Teacher Retirement System of Texas Acquires 3,797 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Teacher Retirement System of Texas boosted its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 12.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 34,979 shares of the biopharmaceutical company’s stock after acquiring an additional 3,797 shares during the quarter. Teacher Retirement System of Texas’ holdings in Dynavax Technologies were worth $447,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Smartleaf Asset Management LLC lifted its holdings in shares of Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 2,034 shares in the last quarter. GAMMA Investing LLC lifted its stake in Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 1,457 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in Dynavax Technologies during the 4th quarter valued at $71,000. Nisa Investment Advisors LLC boosted its holdings in Dynavax Technologies by 19.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 1,076 shares during the last quarter. Finally, KBC Group NV grew its stake in shares of Dynavax Technologies by 68.7% in the 4th quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 2,857 shares in the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on DVAX shares. William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group downgraded Dynavax Technologies from a “neutral” rating to a “sell” rating and cut their target price for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th. StockNews.com raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. Finally, HC Wainwright reiterated a “buy” rating and set a $31.00 price target on shares of Dynavax Technologies in a report on Friday, February 21st.

Dynavax Technologies Stock Down 5.2 %

DVAX opened at $12.97 on Tuesday. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $14.63. The company’s 50-day moving average price is $13.36 and its two-hundred day moving average price is $12.52. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of 72.06 and a beta of 1.23. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting the consensus estimate of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The business had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. As a group, equities analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.